Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Alector Inc (NQ: ALEC )

5.560 +0.140 (+2.58%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 1, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Alector Inc

These biotechs targeting multiple neurodegenerative diseases
A growing number of up-and-coming biotech firms are demonstrating the value of expanding a drug's total addressable market. 
Via MarketBeat
Alector to Host Two Virtual Research and Development Events Highlighting TREM2 and Progranulin Programs
Leading scientific and clinical experts to provide perspectives and rationale for TREM2 and progranulin targets on December 7 and December 13, respectively 
From Alector, Inc.
Via GlobeNewswire
Alector to Participate in the Stifel Healthcare Conference
From Alector, Inc.
Via GlobeNewswire
Alector Reports Third Quarter 2023 Financial Results and Provides Business Update
From Alector, Inc.
Via GlobeNewswire
Alector Announces Achievement of Target Enrollment in the Pivotal INFRONT-3 Phase 3 Clinical Trial of Latozinemab in Individuals with Frontotemporal Dementia Due to a Progranulin Gene Mutation (FTD-GRN)
From Alector, Inc.
Via GlobeNewswire
Alector Announces Completion of Enrollment in the INVOKE-2 Phase 2 Clinical Trial of AL002, a TREM2 Monoclonal Antibody, in Individuals With Early Alzheimer’s Disease
Data readout expected in Q4 2024 
From Alector, Inc.
Via GlobeNewswire
Alector to Participate in Upcoming Healthcare Conferences
From Alector, Inc.
Via GlobeNewswire
Alector Reports Second Quarter 2023 Financial Results and Provides Business Update
From Alector, Inc.
Via GlobeNewswire
Alector to Host Mid-Year Earnings Conference Call
Call Scheduled for Thursday, August 3, 2023, at 4:30 p.m. ET/1:30 p.m. PT 
From Alector, Inc.
Via GlobeNewswire
Alector to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference
From Alector, Inc.
Via GlobeNewswire
Alector Reports First Quarter 2023 Financial Results and Provides Business Update
From Alector, Inc.
Via GlobeNewswire
Alector to Participate in the BofA Securities 2023 Healthcare Conference
From Alector, Inc.
Via GlobeNewswire
Alector to Participate in Upcoming Healthcare Conferences
From Alector, Inc.
Via GlobeNewswire
Alector Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
From Alector, Inc.
Via GlobeNewswire
Alector Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Alector, Inc.
Via GlobeNewswire
Alector Presents Results from First-in-Human Phase 1 Study of AL101 for the Treatment of Neurodegenerative Diseases
From Alector, Inc.
Via GlobeNewswire
Alector Reports Third Quarter 2022 Financial Results and Provides Business Update
From Alector, Inc.
Via GlobeNewswire
Alector to Participate in Upcoming Healthcare Conferences
From Alector, Inc.
Via GlobeNewswire
Alector Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Alector, Inc.
Via GlobeNewswire
Alector Announces Promotion of Clare Hunt to Chief People Officer
From Alector, Inc.
Via GlobeNewswire
Alector Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Alector, Inc.
Via GlobeNewswire
R&D Efforts for Alzheimer’s Therapies on the Rise with over 120 Drugs in Development
Palm Beach, FL – March 31, 2022 – FinancialNewsMedia.com News Commentary – Alzheimer’s disease (AD) is an irreversible, progressive neurodegenerative disease. It is the most common cause of dementia... 
Via FinancialNewsMedia
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.